TNDM · CIK 0001438133
What Tandem Diabetes Care, Inc. told the SEC could break it.
Tandem's disclosures cluster on concentration at both ends of its insulin-pump business. On the way to market it sells largely through independent distributors — 63% of total U.S. sales in 2025 — with two distributors each accounting for more than 10% of worldwide sales, so losing or renegotiating either would materially cut sales until it can shift those volumes (it is beginning a move toward direct operations in 2026). On the supply side, it depends on a small number of component suppliers, some single-sourced and several located in China, Mexico, and Costa Rica, where medical-device qualification makes replacements slow — and that same international footprint exposes it to U.S. tariffs and trade-policy actions that could raise component costs it may be unable to fully pass through.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Two unnamed independent distributors each >10% of worldwide sales; distributors = 63% of U.S. salesmedium
Tandem sells largely through independent distributors rather than direct: sales to distributors accounted for 63% of total U.S. sales in 2025, and for the year ended December 31, 2025 two independent distributors each accounted for more than 10% of worldwide sales. Loss of, or a contract change with, either >10% distributor — or a shift of patients to a single-source diabetes-supply distributor — would materially reduce sales until Tandem can transition those volumes (it is beginning a move toward direct operations in 2026). The distributors are unnamed, so this is a customer-concentration risk rather than a named edge.
“For the year ended December 31, 2025, two independent distributors each accounted for more than 10% of our worldwide sales.”
SEC filing →As of 2026
Regulatory & policy
- Tariff/trade-policy exposure on internationally sourced components (China, Mexico, Costa Rica) plus a Mexico third-party contract manufacturermedium
Tandem's hardware supply chain runs through tariff-sensitive geographies: it sources components from a limited number of suppliers in China, Mexico and Costa Rica and purchases certain inventory from a third-party contract manufacturer located in Mexico. It states that depending on a limited number of (partly international) suppliers exposes it to limited control over costs, including tariffs. New or increased U.S. tariffs (China Section 301, USMCA-region actions) on these imports would raise component/landed costs it may be unable to fully pass through. A quantified-geography trade-policy/tariff exposure on a hardware medical device.
“Depending on a limited number of suppliers exposes us to risks, including limited control over costs, including tariffs, availability, quality and delivery schedules.”
Supplier concentration
- Small number of component suppliers (some single-sourced) for an FDA-regulated device; medical-device qualification makes replacement slowmedium
Tandem depends on a small number of suppliers for the components and sub-assemblies of its insulin pumps, some single-sourced and some located internationally (China, Mexico, Costa Rica). Because medical-device manufacturing qualification is required, it may not be able to quickly establish additional or replacement sources; for sole-sourced parts it mitigates by holding inventory in-house and at the supplier. A supplier disruption, quality failure, or loss of a sole-source component vendor could halt pump production. Suppliers (other than Unomedical, captured as an edge) are unnamed, so this is a supplier-concentration/sole-source risk.
“We generally use a small number of suppliers for our components and products, some of which are located internationally, including in China, Mexico and Costa Rica.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Unomedical A/S (ConvaTec Group)
“infusion sets from a third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group. Unomedical is responsible for all manufacturing, testing, sterilization and packaging of the infusion sets under our brands.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch